See more : Yum China Holdings, Inc. (0M30.L) Income Statement Analysis – Financial Results
Complete financial analysis of Ceapro Inc. (CRPOF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ceapro Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- STAG Industrial, Inc. (STAG) Income Statement Analysis – Financial Results
- Guangzhou Hengyun Enterprises Holding Ltd (000531.SZ) Income Statement Analysis – Financial Results
- BioCardia, Inc. (BCDA) Income Statement Analysis – Financial Results
- The Okinawa Electric Power Company, Incorporated (OKEPF) Income Statement Analysis – Financial Results
- Encision Inc. (ECIA) Income Statement Analysis – Financial Results
Ceapro Inc. (CRPOF)
About Ceapro Inc.
Ceapro Inc., a biotechnology company, engages in the development and marketing of health and wellness products and technology relating to plant extracts in the United States, Germany, China, Canada, and internationally. It operates in two segments, Active Ingredient Product Technology Industry and Cosmeceutical Industry. The Active Ingredient Product Technology Industry segment develops proprietary extraction technologies and the application of these technologies to the production, development, and commercialization of active ingredients, such as oat beta glucan and avenanthramides, which are derived from oats and other renewable plant resources for healthcare and cosmetic industries. The Cosmeceutical Industry segment is involved in the development and commercialization of anti-aging products derived from natural active ingredients sold directly to the end-user primarily through online website sales and through select natural products stores. The company was incorporated in 1997 and is headquartered in Edmonton, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.63M | 18.84M | 17.20M | 15.12M | 12.88M | 11.59M | 12.93M | 13.67M | 10.67M | 8.89M | 6.52M | 5.17M | 5.79M | 5.58M | 4.37M | 4.23M | 3.45M | 3.31M | 2.68M | 1.96M | 2.22M | 1.51M | 1.15M | 808.85K | 300.00K | 400.00K | 2.30M | 600.00K |
| Cost of Revenue | 6.07M | 7.82M | 7.51M | 7.50M | 7.43M | 5.45M | 5.65M | 4.32M | 3.64M | 4.13M | 3.43M | 2.72M | 2.54M | 3.04M | 2.25M | 2.64M | 1.79M | 1.73M | 1.12M | 1.02M | 928.12K | 754.13K | 728.41K | 517.68K | 200.00K | 100.00K | 1.90M | 500.00K |
| Gross Profit | 3.56M | 11.02M | 9.69M | 7.62M | 5.45M | 6.14M | 7.27M | 9.35M | 7.03M | 4.76M | 3.10M | 2.45M | 3.25M | 2.54M | 2.12M | 1.59M | 1.65M | 1.58M | 1.56M | 934.13K | 1.29M | 757.38K | 421.03K | 291.17K | 100.00K | 300.00K | 400.00K | 100.00K |
| Gross Profit Ratio | 36.99% | 58.48% | 56.35% | 50.41% | 42.28% | 52.95% | 56.26% | 68.40% | 65.89% | 53.58% | 47.50% | 47.41% | 56.13% | 45.46% | 48.47% | 37.53% | 47.97% | 47.70% | 58.13% | 47.73% | 58.16% | 50.11% | 36.63% | 36.00% | 33.33% | 75.00% | 17.39% | 16.67% |
| Research & Development | 2.75M | 1.79M | 3.78M | 1.88M | 2.39M | 2.67M | 1.61M | 919.12K | 625.21K | 578.36K | 731.17K | 856.19K | 996.72K | 774.06K | 0.00 | 0.00 | 695.66K | 365.42K | 162.83K | 302.49K | 353.74K | 259.06K | 397.00K | 293.43K | 400.00K | 800.00K | 2.30M | 100.00K |
| General & Administrative | 7.42M | 3.70M | 3.24M | 3.28M | 2.95M | 3.00M | 2.84M | 2.19M | 2.52M | 1.98M | 1.71M | 1.80M | 1.37M | 1.30M | 1.68M | 1.69M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 40.48K | 29.56K | 47.12K | 111.04K | 425.23K | 225.55K | 32.11K | 4.33K | 7.62K | 13.70K | 84.90K | 198.65K | 111.36K | 69.51K | 183.69K | 385.13K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.07M | 3.73M | 3.29M | 3.39M | 3.38M | 3.23M | 2.87M | 2.19M | 2.53M | 2.00M | 1.79M | 1.99M | 1.49M | 1.37M | 1.86M | 2.07M | 1.68M | 1.36M | 1.24M | 963.92K | 1.27M | 814.11K | 691.92K | 777.79K | 800.00K | 1.10M | 3.70M | 1.80M |
| Other Expenses | 129.31K | 181.46K | 273.12K | -93.71K | -353.32K | -1.12M | -738.09K | -629.30K | 0.00 | 0.00 | 0.00 | 0.00 | -7.34K | -479.44K | -219.38K | -2.29M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 9.82M | 5.52M | 7.07M | 5.28M | 5.77M | 5.17M | 6.63M | 3.11M | 3.15M | 2.58M | 2.53M | 2.85M | 2.48M | 1.43M | 1.90M | 2.81M | 2.17M | 1.87M | 1.56M | 1.36M | 1.68M | 1.10M | 1.11M | 1.10M | 1.20M | 2.00M | 8.20M | 2.20M |
| Cost & Expenses | 15.89M | 13.34M | 14.57M | 12.77M | 13.21M | 10.62M | 12.29M | 7.43M | 6.79M | 6.70M | 5.95M | 5.57M | 5.02M | 4.47M | 4.16M | 5.45M | 3.96M | 3.61M | 2.69M | 2.38M | 2.61M | 1.85M | 1.84M | 1.62M | 1.40M | 2.10M | 10.10M | 2.70M |
| Interest Income | 436.22K | 93.20K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 12.55K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 100.00K |
| Interest Expense | 128.13K | 129.97K | 151.89K | 175.16K | 201.50K | 48.05K | 20.03K | 37.59K | 52.78K | 63.51K | 126.66K | 112.90K | 180.81K | 110.90K | 77.03K | 83.65K | 43.83K | 46.35K | 51.70K | 28.50K | 47.77K | 93.56K | 113.22K | 94.93K | 0.00 | 100.00K | 0.00 | 100.00K |
| Depreciation & Amortization | 1.95M | 1.91M | 1.88M | 1.84M | 1.83M | 578.60K | 326.10K | 359.45K | 392.32K | 296.38K | 292.64K | 292.53K | 297.28K | 290.64K | 356.96K | 336.57K | 120.44K | 146.78K | 161.55K | 91.96K | 59.96K | 23.57K | 24.25K | 27.99K | 0.00 | 100.00K | 2.20M | 300.00K |
| EBITDA | -4.31M | 7.54M | 4.72M | 4.04M | 1.10M | 371.48K | 110.92K | 6.40M | 4.08M | 2.36M | 866.33K | -109.12K | 1.06M | 1.41M | 571.46K | -889.10K | -393.57K | -148.94K | 158.33K | -332.28K | -330.37K | -315.78K | -667.88K | -780.05K | -1.10M | -1.60M | -5.60M | -1.80M |
| EBITDA Ratio | -44.73% | 40.00% | 27.46% | 26.71% | 8.52% | 3.20% | 0.86% | 46.78% | 38.20% | 26.54% | 13.28% | -2.11% | 18.37% | 25.22% | 13.08% | -21.03% | -11.42% | -4.50% | 5.90% | -16.98% | -14.89% | -20.89% | -58.10% | -96.44% | -366.67% | -400.00% | -243.48% | -300.00% |
| Operating Income | -6.26M | 5.31M | 2.42M | 2.12M | -586.66K | 128.08K | 2.66M | 6.00M | 3.63M | 2.00M | 447.03K | -514.55K | 584.91K | 992.80K | 137.47K | -1.31M | -514.01K | 21.64K | -3.22K | -424.24K | -390.33K | -339.35K | -692.14K | -808.04K | -1.10M | -1.70M | -7.80M | -2.10M |
| Operating Income Ratio | -64.93% | 28.21% | 14.05% | 13.99% | -4.55% | 1.10% | 20.55% | 43.87% | 34.03% | 22.49% | 6.85% | -9.96% | 10.11% | 17.80% | 3.15% | -30.97% | -14.91% | 0.65% | -0.12% | -21.68% | -17.60% | -22.45% | -60.21% | -99.90% | -366.67% | -425.00% | -339.13% | -350.00% |
| Total Other Income/Expenses | 350.72K | 277.94K | -4.61K | -490.51K | -810.06K | -1.05M | -1.07M | -878.91K | -658.56K | -596.51K | -401.99K | -23.81K | -7.34K | 310.10K | -219.38K | -2.29M | -875.32K | -294.00K | -53.79K | 26.51K | 553.01K | 462.33K | 459.25K | -12.92K | 100.00K | -12.50M | -11.00M | -1.40M |
| Income Before Tax | -5.90M | 5.78M | 2.62M | 1.86M | -1.14M | -921.23K | -426.82K | 5.36M | 3.83M | 1.59M | 175.81K | -538.35K | 577.57K | 501.08K | -81.90K | -3.60M | -1.39M | -272.36K | -57.01K | -397.74K | 442.04K | 115.77K | -232.88K | -820.96K | -1.00M | -14.20M | -18.80M | -3.50M |
| Income Before Tax Ratio | -61.29% | 30.66% | 15.23% | 12.27% | -8.82% | -7.95% | -3.30% | 39.22% | 35.94% | 17.93% | 2.69% | -10.42% | 9.98% | 8.99% | -1.87% | -85.13% | -40.30% | -8.23% | -2.12% | -20.32% | 19.93% | 7.66% | -20.26% | -101.50% | -333.33% | -3,550.00% | -817.39% | -583.33% |
| Income Tax Expense | -1.19M | 1.38M | -223.69K | 81.45K | -3.41K | -605.69K | 531.46K | 1.74M | -1.09M | 63.51K | 126.66K | 112.90K | 180.81K | 123.18K | 64.48K | 83.65K | 369.93K | 46.35K | 51.70K | 28.50K | 47.77K | 93.56K | 113.22K | 94.93K | -100.00K | 100.00K | 1.00M | 200.00K |
| Net Income | -4.71M | 4.40M | 3.37M | 1.86M | -1.13M | -315.54K | -958.28K | 3.62M | 4.92M | 1.59M | 175.81K | -538.35K | 577.57K | 463.72K | -69.35K | -3.60M | -1.39M | -272.36K | -57.01K | -397.74K | 442.04K | 115.77K | -346.10K | -915.90K | -900.00K | -14.30M | -19.80M | -3.70M |
| Net Income Ratio | -48.89% | 23.34% | 19.57% | 12.27% | -8.79% | -2.72% | -7.41% | 26.47% | 46.14% | 17.93% | 2.69% | -10.42% | 9.98% | 8.32% | -1.59% | -85.13% | -40.30% | -8.23% | -2.12% | -20.32% | 19.93% | 7.66% | -30.11% | -113.23% | -300.00% | -3,575.00% | -860.87% | -616.67% |
| EPS | -0.06 | 0.06 | 0.04 | 0.02 | -0.01 | 0.00 | -0.01 | 0.05 | 0.08 | 0.03 | 0.00 | -0.01 | 0.01 | 0.01 | 0.00 | -0.08 | -0.03 | -0.01 | 0.00 | -0.01 | 0.01 | 0.00 | -0.01 | -0.04 | -0.04 | -0.79 | -1.27 | -0.20 |
| EPS Diluted | -0.06 | 0.06 | 0.04 | 0.02 | -0.01 | 0.00 | -0.01 | 0.05 | 0.08 | 0.03 | 0.00 | -0.01 | 0.01 | 0.01 | 0.00 | -0.08 | -0.03 | -0.01 | 0.00 | -0.01 | 0.01 | 0.00 | -0.01 | -0.04 | -0.04 | -0.79 | -1.27 | -0.20 |
| Weighted Avg Shares Out | 78.27M | 77.96M | 77.67M | 77.59M | 77.19M | 76.20M | 75.34M | 67.68M | 61.80M | 60.90M | 60.28M | 60.28M | 56.56M | 53.22M | 49.58M | 47.05M | 42.34M | 37.19M | 36.34M | 39.77M | 31.57M | 28.94M | 29.36M | 21.23M | 22.50M | 18.10M | 15.59M | 18.50M |
| Weighted Avg Shares Out (Dil) | 78.27M | 78.58M | 78.59M | 78.14M | 77.19M | 76.20M | 75.34M | 71.33M | 65.20M | 62.53M | 60.28M | 60.28M | 56.56M | 53.22M | 49.58M | 47.05M | 42.34M | 37.19M | 36.34M | 39.77M | 34.00M | 28.94M | 29.36M | 21.23M | 22.50M | 18.10M | 15.59M | 18.50M |
Ceapro Inc. to Present at the H.C. Wainwright Global Investment Conference
EDMONTON, Alberta, May 23, 2022 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced that Gilles...
Ceapro Inc. to Present at the Virtual Investor 2022 Top Picks Conference
Live video webcast presentation on Thursday, January 27th at 3:00 PM ET Live video webcast presentation on Thursday, January 27th at 3:00 PM ET
Ceapro Inc. to Present at the Virtual Investor Roundtable Event
Live moderated video webcast discussion on Wednesday, November 17th at 11:00 AM ET Live moderated video webcast discussion on Wednesday, November 17th at 11:00 AM ET
Ceapro Inc. Reports 2021 Second Quarter and Six-Month Financial Results and Operational Highlights
– Company continues to increase R&D activities to advance clinical and preclinical programs –
Ceapro Inc. Enters into Research Collaboration with the Angiogenesis Foundation for Beta Glucan and Avenanthramides
– Research focused on addressing root cause of disease and tissue damage for diseases such as COVID-19 –
Ceapro Inc. Expands Collaboration with Montreal Heart Institute (MHI) with New Clinical Study Evaluating Flagship Product, Avenanthramide
- Second human trial to be conducted as part of a long-term Master Service Agreement with MHI - Phase 1 study with Ceapro's pharmaceutical grade avenanthramide to be coordinated by MHI's Montreal Health Innovations Coordinating Center (MHICC) and led by...
Ceapro Announces Results of 2021 Shareholders' Meeting
EDMONTON, Alberta, June 01, 2021 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that all...
Ceapro Inc. Reports 2021 First Quarter Financial Results and Highlights
– Maintained production operations during COVID-19 pandemic, providing customers essential products while ensuring the health and safety of Company's employees –
Ceapro Inc. Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights
EDMONTON, Alberta, April 22, 2021 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO, OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced operational highlights...
Ceapro Inc. Announces Successful Completion of Collaborative Research and Development Program with University of Alberta
– Project significantly advances broadening the application and utility of Ceapro's proprietary, first-in-class technologies to develop innovative delivery systems composed of new chemical complexes –
Source: https://incomestatements.info
Category: Stock Reports